GlassScriptPhysician profile
Jennifer Bell
NPI 1285054171
$3,331.63
in general payments reported to CMS, 2019-2025
18 companies · $770 in 2025
The $770 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $222 · 2021: $405 · 2022: $623 · 2023: $617 · 2024: $369 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737 · Education: $18.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.38 |
| Education | $18.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $990.71 | 2019-2024 | Cardiomems |
| Astrazeneca Pharmaceuticals LP | $302.53 | 2021-2025 | Wainua, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $281.83 | 2022-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $280.72 | 2022-2025 | Onpattro |
| Abiomed | $237.73 | 2021-2025 | |
| Pfizer INC. | $214.37 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.66 | 2022-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $212.36 | 2022-2025 | Opsumit, Uptravi |
| Amgen INC. | $115.06 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $84.38 | 2023-2024 | Inpefa |
| Impulse Dynamics (USA) INC. | $82.89 | 2022-2023 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $78.37 | 2023-2025 | |
| Bridgebio Pharma, INC. | $76.25 | 2025 | Attruby |
| Novo Nordisk INC | $73.66 | 2025 | Wegovy |
| Tandem Diabetes Care, INC. | $26.40 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.73 | 2021 | |
| Merck Sharp & Dohme LLC | $20.01 | 2023 | Verquvo |
| Scpharmaceuticals INC. | $16.97 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.